🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06308484
Recruiting Not applicable

Neuromodulation and Mindfulness Patients With AUD

NCT06308484 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2024-03-20
Last updated
2026-03-20

Condition(s) studied

Alcohol Dependence

Investigational drug(s) / intervention(s)

Transcutaneous vagus nerve stimulationClosed-loop AM-tACS

Transcutaneous vagus nerve stimulation: Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.

Closed-loop AM-tACS: Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.

Study summary

Our primary objective is to integrate tVNS and mindfulness meditation within a structured mindfulness-based relapse prevention (MBRP) program for detoxified alcohol-dependent patients (AD). We aim to determine whether neuromodulation can enhance mindfulness-based relapse prevention compared to mindfulness practice alone. In this context, we will investigate potential changes in the interaction of top-down control and cue reactivity, as well as assess the severity of AUD. Measurements of drinking behavior, cravings, and abstinence rates will be conducted up to three months post-treatment. Our second objective is to examine the causal role of frontal midline theta oscillations (FMΘ) in MBRP and cognitive control. To achieve this, we will first establish closed-loop amplitude-modulated transcranial alternating current stimulation (CLAM-tACS) to selectively modulate FMΘ oscillations during MBRP meditation exercises in AUD patients (2).

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Alcohol Dependence (ICD-10) * abstinence between 3 days and 12 months Exclusion Criteria: * current (last 12 months) substance use disorder/dependence * neurological disorders (e.g. epilepsy, neuropathy, multiple sclerosis) * current severe major depressive disorder, manic episode or schizophreniform disorder * intake of anticonvulsive or high-potency antipsychotic medication

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Charité - Berlin University of Medicine Berlin State of Berlin Recruiting

More Charite University, Berlin, Germany trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06308484 on ClinicalTrials.gov ↗ ← All trials in Germany